39 (76) 591 (60) Race, n (%) 
Results

Results (cont'd) Objectives
To perform a retrospective analysis to compare safety, efficacy, and adherence with SOF/VEL treatment in patients receiving or not receiving OST
The Phase 3 ASTRAL studies demonstrated that treatment with the once-daily fixed-dose combination tablet of sofosbuvir (SOF)/velpatasvir(VEL) was well tolerated and resulted in SVR12 rates >95% across all hepatitis C virus (HCV) genotypes
1-3
HCV infection is highly prevalent in patients with history of injection drug use, including those receiving opioid substitution therapy (OST) Neither SOF nor VEL has significant drug-drug interactions with medications commonly used for OST and, therefore, patients on OST were not excluded from the ASTRAL clinical program
Introduction Methods
A retrospective analysis was performed using data from SOF/VELtreated patients in ASTRAL-1, -2, and -3 (ClinicalTrials.gov NCT02201940, NCT02220998, and NCT02201953, respectively) Records of concomitant medications reviewed for use of OST (including methadone, buprenorphine) People with clinically relevant illicit drug use within 12 months or a positive urine drug screen at screening were excluded. No drug screens were performed during or following treatment.
Frequency and severity of treatment-emergent adverse events (AEs) and laboratory abnormalities compared between SOF/VEL-treated patients on and not on OST Virologic outcomes (SVR12, virologic failure) calculated for patients on and not on OST Adherence to SOF/VEL calculated using pill count at every visit for patients on and not on OST Deep sequencing of HCV NS5A/NS5B was performed for all patients at baseline and at virologic failure to distinguish viral relapse from reinfection Demographics BMI, body mass index; IL28B, interleukin-28B.
Patients on OST were younger and included a greater proportion of men than those not on OST
HCV Genotype
GT, genotype.
HCV genotype 3 predominated in patients on OST 
SVR12 by HCV Genotype in Patients on OST
*Error bars represent 95% CIs.
Safety
The proportion with AEs (86% vs 79%, p=0.29) were similar among participants receiving and not receiving OST. The proportion with serious AEs (6% vs. 2%, p=0.10) were higher in those receiving OST, but not statistically significant Serious adverse events in those receiving OST included abdominal pain (n=1), bronchitis (n=1), and palpitations (n=1)
